<p>4D Molecular Therapeutics, Inc.（纳斯达克代码：FDMT - 获取免费报告）在周二的午盘交易中下跌了 5.3%。该公司的股价最低曾达到$10.53，最后交易价为$10.4930。午盘交易期间大约交易了 523,751 股，较平均每日交易量 852,534 股下降了 39%。该股票此前收盘价为$11.08。</p>
<h2>分析师评级调整</h2>
<p>几位研究分析师对该股票发布了报告。加拿大皇家银行在 11 月 11 日的研究报告中将 4D Molecular Therapeutics 的目标价从$26.00 上调至$32.00，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 4D Molecular Therapeutics 的 “卖出（d-）” 评级。Roth Capital 在 8 月 12 日的研究报告中将 4D Molecular Therapeutics 的目标价从$44.00 下调至$38.00，并对该股票给予 “买入” 评级。摩根士丹利在 11 月 7 日的研究报告中将 4D Molecular Therapeutics 的评级从 “减持” 上调至 “持平”。最后，Leerink Partners 在 10 月 31 日的研究报告中重申了 “跑赢大盘” 的评级，并设定了$17.00 的目标价。八位研究分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为$28.70。</p>
<p><strong>阅读我们关于 FDMT 的最新报告</strong></p>
<h2>4D Molecular Therapeutics 价格表现</h2>
<p>该股票的 50 日简单移动平均线为$10.43，200 日简单移动平均线为$7.13。该公司的市值为 6.0015 亿美元，市盈率为-2.79，贝塔值为 2.96。</p>
<p>4D Molecular Therapeutics（纳斯达克代码：FDMT - 获取免费报告）在 11 月 10 日发布了季度财报。该公司报告季度每股收益（EPS）为 ($1.01)，超出市场共识预期的 ($1.02) $0.01。4D Molecular Therapeutics 的净利润率为-174,314.17%，股本回报率为-47.27%。该公司在本季度的收入为$0.09 百万，而分析师预期为$0.40 百万。平均而言，卖方分析师预测 4D Molecular Therapeutics, Inc.在当前年度将发布-2.84 的每股收益。</p>
<h2>4D Molecular Therapeutics 的内部交易</h2>
<p>在相关消息中，内部人士 Scott Bizily 在 10 月 24 日的交易中出售了 2,678 股该公司的股票。股票以平均价格$12.00 出售，总交易额为$32,136.00。交易完成后，该内部人士直接持有该公司 3,594 股，价值约$43,128。这笔交易代表了他们持股比例的 42.70% 的减少。该交易已在 SEC 的备案中披露，相关信息可在 SEC 网站上查阅。内部人士在上个季度出售了 10,763 股公司股票，价值$109,415。9.60% 的股票由内部人士持有。</p>
<h2>机构投资者对 4D Molecular Therapeutics 的看法</h2>
<p>大型投资者最近增加或减少了对该股票的持股。Wexford Capital LP 在第三季度购买了 4D Molecular Therapeutics 的新头寸，价值约$41,000。Farther Finance Advisors LLC 在第三季度将其在 4D Molecular Therapeutics 的持股增加了 117.4%。Farther Finance Advisors LLC 现在拥有 4,952 股该公司的股票，价值$43,000，此前在上个季度又购买了 2,674 股。Abich Financial Wealth Management LLC 在第三季度获得了 4D Molecular Therapeutics 的新头寸，价值约$80,000。Inscription Capital LLC 在第三季度获得了 4D Molecular Therapeutics 的新头寸，价值$94,000。最后，Impact Partnership Wealth LLC 在第三季度购买了 4D Molecular Therapeutics 的新股份，价值$96,000。机构投资者持有该公司 99.27% 的股票。</p>
<h2>4D Molecular Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>4D Molecular Therapeutics, Inc.是一家临床阶段的生物治疗公司，利用其治疗性载体进化平台在荷兰和美国开发基因药物。该公司开发了一系列基因药物候选产品，专注于眼科、心脏病学和肺病学三个治疗领域。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票而非 4D Molecular Therapeutics</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>办公套件价格上涨：微软的大胆举措伴随风险</li>
<li>什么是特别股息？</li>
<li>IBM 的重大赌注：以 110 亿美元收购 AI 神经系统</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>Carvana 从低点飙升超过 10,000%——现在它进入了标准普尔 500 指数</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 4D Molecular Therapeutics 吗？</h2>
<p>在你考虑 4D Molecular Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 4D Molecular Therapeutics 并不在名单上。</p>
<p>虽然 4D Molecular Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

FDMT

<p>4D Molecular Therapeutics (NASDAQ:FDMT) 的股票在午盘交易中下跌了 5.3%，交易量显著减少。分析师的评级不一，普遍共识为 “适度买入”，目标价为 28.70 美元。该公司报告的季度每股收益为（$1.01），略好于预期。内部交易和机构投资值得注意，内部人士持有 9.60% 的股份</p>

<p>4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) was down 5.3% during mid-day trading on Tuesday . The company traded as low as $10.53 and last traded at $10.4930. Approximately 523,751 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 852,534 shares. The stock had previously closed at $11.08.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics, Inc.（纳斯达克代码：FDMT - 获取免费报告）在周二的午盘交易中下跌了 5.3%。该公司的股价最低曾达到$10.53，最后交易价为$10.4930。午盘交易期间大约交易了 523,751 股，较平均每日交易量 852,534 股下降了 39%。该股票此前收盘价为$11.08。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several research analysts have issued reports on the stock. Royal Bank Of Canada raised their price objective on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, November 11th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Roth Capital decreased their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, August 12th. Morgan Stanley raised 4D Molecular Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating in a research note on Friday, November 7th. Finally, Leerink Partners restated an &#34;outperform&#34; rating and set a $17.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $28.70.</p>
<div class="lb-trans"><p>几位研究分析师对该股票发布了报告。加拿大皇家银行在 11 月 11 日的研究报告中将 4D Molecular Therapeutics 的目标价从$26.00 上调至$32.00，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 4D Molecular Therapeutics 的 “卖出（d-）” 评级。Roth Capital 在 8 月 12 日的研究报告中将 4D Molecular Therapeutics 的目标价从$44.00 下调至$38.00，并对该股票给予 “买入” 评级。摩根士丹利在 11 月 7 日的研究报告中将 4D Molecular Therapeutics 的评级从 “减持” 上调至 “持平”。最后，Leerink Partners 在 10 月 31 日的研究报告中重申了 “跑赢大盘” 的评级，并设定了$17.00 的目标价。八位研究分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为$28.70。</p>
</div><p><strong>Read Our Latest Report on FDMT</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 FDMT 的最新报告</strong></p>
</div><h2>4D Molecular Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 价格表现</h2>
</div><p>The stock's fifty day simple moving average is $10.43 and its two-hundred day simple moving average is $7.13. The company has a market capitalization of $600.15 million, a price-to-earnings ratio of -2.79 and a beta of 2.96.</p>
<div class="lb-trans"><p>该股票的 50 日简单移动平均线为$10.43，200 日简单移动平均线为$7.13。该公司的市值为 6.0015 亿美元，市盈率为-2.79，贝塔值为 2.96。</p>
</div><p>4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics（纳斯达克代码：FDMT - 获取免费报告）在 11 月 10 日发布了季度财报。该公司报告季度每股收益（EPS）为 ($1.01)，超出市场共识预期的 ($1.02) $0.01。4D Molecular Therapeutics 的净利润率为-174,314.17%，股本回报率为-47.27%。该公司在本季度的收入为$0.09 百万，而分析师预期为$0.40 百万。平均而言，卖方分析师预测 4D Molecular Therapeutics, Inc.在当前年度将发布-2.84 的每股收益。</p>
</div><h2>Insider Transactions at 4D Molecular Therapeutics</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 的内部交易</h2>
</div><p>In related news, insider Scott Bizily sold 2,678 shares of the firm's stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the completion of the sale, the insider directly owned 3,594 shares in the company, valued at approximately $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 10,763 shares of company stock worth $109,415 over the last quarter. 9.60% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Scott Bizily 在 10 月 24 日的交易中出售了 2,678 股该公司的股票。股票以平均价格$12.00 出售，总交易额为$32,136.00。交易完成后，该内部人士直接持有该公司 3,594 股，价值约$43,128。这笔交易代表了他们持股比例的 42.70% 的减少。该交易已在 SEC 的备案中披露，相关信息可在 SEC 网站上查阅。内部人士在上个季度出售了 10,763 股公司股票，价值$109,415。9.60% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On 4D Molecular Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 4D Molecular Therapeutics 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $41,000. Farther Finance Advisors LLC lifted its holdings in 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock valued at $43,000 after purchasing an additional 2,674 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $80,000. Inscription Capital LLC acquired a new position in 4D Molecular Therapeutics in the third quarter worth $94,000. Finally, Impact Partnership Wealth LLC bought a new stake in shares of 4D Molecular Therapeutics during the third quarter worth $96,000. Institutional investors own 99.27% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该股票的持股。Wexford Capital LP 在第三季度购买了 4D Molecular Therapeutics 的新头寸，价值约$41,000。Farther Finance Advisors LLC 在第三季度将其在 4D Molecular Therapeutics 的持股增加了 117.4%。Farther Finance Advisors LLC 现在拥有 4,952 股该公司的股票，价值$43,000，此前在上个季度又购买了 2,674 股。Abich Financial Wealth Management LLC 在第三季度获得了 4D Molecular Therapeutics 的新头寸，价值约$80,000。Inscription Capital LLC 在第三季度获得了 4D Molecular Therapeutics 的新头寸，价值$94,000。最后，Impact Partnership Wealth LLC 在第三季度购买了 4D Molecular Therapeutics 的新股份，价值$96,000。机构投资者持有该公司 99.27% 的股票。</p>
</div><h2>4D Molecular Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics, Inc.是一家临床阶段的生物治疗公司，利用其治疗性载体进化平台在荷兰和美国开发基因药物。该公司开发了一系列基因药物候选产品，专注于眼科、心脏病学和肺病学三个治疗领域。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than 4D Molecular Therapeutics</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Office Suite Gets Pricier: Microsoft’s Bold Move Comes With Risk</li>
<li>What is a Special Dividend?</li>
<li>Big Blue’s Big Bet: IBM Buys AI Nervous System for $11B</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Carvana Soars Over 10,000% From Lows—Now It’s in the S&amp;P 500</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 4D Molecular Therapeutics</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>办公套件价格上涨：微软的大胆举措伴随风险</li>
<li>什么是特别股息？</li>
<li>IBM 的重大赌注：以 110 亿美元收购 AI 神经系统</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>Carvana 从低点飙升超过 10,000%——现在它进入了标准普尔 500 指数</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 4D Molecular Therapeutics 吗？</h2>
</div><p>Before you consider 4D Molecular Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 4D Molecular Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 4D Molecular Therapeutics 并不在名单上。</p>
</div><p>While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 4D Molecular Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

4D Molecular Therapeutics (NASDAQ:FDMT) 股价下跌 5.3% - 以下是原因